Skip to main content

Combo Methotrexate and Leflunomide Safety in RA

Jul 28, 2021

Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide. A recent study of combination therapy with MTX and LEF underscores the efficacy and safety of this approach and

Read Article
Another report of JAK inhibitor working in GVHD - Successful treatmente of joint & fascial involvement in GVHD with baricitinib. https://t.co/TQlPLCD2T7 https://t.co/474GpFKBo2

Dr. John Cush @RheumNow( View Tweet )

Jul 27, 2021
FDA delays in the analysis of Pfizers/Xeljanz Oral Surveillance Safety study has put off potential approvals for other JAKs (Lillys Oluminant in Eczema & Abbvies Rinvoq for Eczema, Psoriatic arthritis, Ank Spondylitis). The wait continues.. https://t.co/3pRp2Vnuhw

Dr. John Cush @RheumNow( View Tweet )

Jul 20, 2021

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

Jul 09, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

ICYMI: Psoriatic Disease Management - RNL 2021 Highlights

Jul 08, 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article

ICYMI: New GRAPPA 2021 PsO and PsA Treatment Recommendations

Jul 07, 2021

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients

Read Article

ICYMI: Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

Jul 05, 2021

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to at-

Read Article

ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jul 05, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article

RheumNow Podcast – As Good As I Ever Was (7.2.2021)

Jul 02, 2021

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jun 25, 2021

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
FINCH 1 Trial Filgotinib in Rheumatoid Arthritis The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the JAK1 preferential inhibitor filgotinib was superior to adalimumab in active RA on MTX. https://t.co/d501qhArfP https://t.co/YGH5LQDGbs
Dr. John Cush @RheumNow( View Tweet )
Jun 23, 2021

FINCH 1 Trial Filgotinib in Rheumatoid Arthritis

Jun 22, 2021

The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).

Read Article
Trial Design for Better Decision-making Using JAKi: Dr. Kerschbaumer and Dr. Studenic https://t.co/NtXZEJM4vg https://t.co/QOaxBPebz6
Dr. John Cush @RheumNow( View Tweet )
Jun 21, 2021

Tofacitinib Efficacy in COVID-19 Pneumonia

Jun 21, 2021

NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.



This multicenter trial was conducted in Brazil. A total of 289 hospitalized

Read Article
When should you use a JAK inhibitor in RA? Dr. Janet Pope ( @Janetbirdope ) shares #EULAR2021 presentations. https://t.co/qF2tjQXLk1 https://t.co/AqJ1dMWV3t
Dr. John Cush @RheumNow( View Tweet )
Jun 17, 2021

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021. But be careful of what you read because depending on age, gender, comorbidities, line of therapy and access to treatment, you may find highly variable

Read Article
Do Patients on Upadacitinib Need Labs? Dr. Janet Pope from Canada, discusses abstract OP00128 presented at the virtual #EULAR2021. https://t.co/mxPzeQXZk7 https://t.co/qz9KiYfTCu
Dr. John Cush @RheumNow( View Tweet )
Jun 14, 2021

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article

RA after 70: Too Old for bioDMARDs?

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.



Importantly, treating people living with RMDs above the age of 70 -

Read Article
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT
EnvisionRheumat @ERheumat( View Tweet )
Jun 06, 2021
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
×